Tags

Type your tag names separated by a space and hit enter

Nonalcoholic steatohepatitis: what we know in the new millennium.
Am J Gastroenterol. 2002 Nov; 97(11):2714-24.AJ

Abstract

Nonalcoholic steatohepatitis (NASH) is a liver disease characterized by diffuse fatty infiltration and inflammation. The exact prevalence of NASH is unclear, but it is becoming more evident that the disease is much more common than previously thought. Although generally a benign, indolent process, it can progress to advanced liver disease in approximately 15-20% of patients. Clinical characteristics associated with NASH include obesity, hyperlipidemia, diabetes mellitus, and hypertension, all of which have been associated with underlying insulin resistance. Typically, this disease becomes evident in the fourth or fifth decade of life with an equal sex predilection. NASH is thought to be caused, in part, by impaired insulin signaling, leading to elevated circulating insulin levels and subsequent altered lipid homeostasis. This process is likely multifactorial and includes both genetic and environmental factors. Treatment options to date are limited and are based on very small clinical trials. Current investigations are focusing on improving the underlying insulin resistance that has been associated with NASH as well as other therapies that decrease oxidative stress or improve hepatocyte survival.

Authors+Show Affiliations

Department of Gastroenterology, Brooke Army Medical Center, Fort Sam Houston, Texas 78234, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

12425538

Citation

Harrison, Stephen A., et al. "Nonalcoholic Steatohepatitis: what We Know in the New Millennium." The American Journal of Gastroenterology, vol. 97, no. 11, 2002, pp. 2714-24.
Harrison SA, Kadakia S, Lang KA, et al. Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol. 2002;97(11):2714-24.
Harrison, S. A., Kadakia, S., Lang, K. A., & Schenker, S. (2002). Nonalcoholic steatohepatitis: what we know in the new millennium. The American Journal of Gastroenterology, 97(11), 2714-24.
Harrison SA, et al. Nonalcoholic Steatohepatitis: what We Know in the New Millennium. Am J Gastroenterol. 2002;97(11):2714-24. PubMed PMID: 12425538.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Nonalcoholic steatohepatitis: what we know in the new millennium. AU - Harrison,Stephen A, AU - Kadakia,Shailesh, AU - Lang,Kevin A, AU - Schenker,Steven, PY - 2002/11/12/pubmed PY - 2002/11/26/medline PY - 2002/11/12/entrez SP - 2714 EP - 24 JF - The American journal of gastroenterology JO - Am J Gastroenterol VL - 97 IS - 11 N2 - Nonalcoholic steatohepatitis (NASH) is a liver disease characterized by diffuse fatty infiltration and inflammation. The exact prevalence of NASH is unclear, but it is becoming more evident that the disease is much more common than previously thought. Although generally a benign, indolent process, it can progress to advanced liver disease in approximately 15-20% of patients. Clinical characteristics associated with NASH include obesity, hyperlipidemia, diabetes mellitus, and hypertension, all of which have been associated with underlying insulin resistance. Typically, this disease becomes evident in the fourth or fifth decade of life with an equal sex predilection. NASH is thought to be caused, in part, by impaired insulin signaling, leading to elevated circulating insulin levels and subsequent altered lipid homeostasis. This process is likely multifactorial and includes both genetic and environmental factors. Treatment options to date are limited and are based on very small clinical trials. Current investigations are focusing on improving the underlying insulin resistance that has been associated with NASH as well as other therapies that decrease oxidative stress or improve hepatocyte survival. SN - 0002-9270 UR - https://www.unboundmedicine.com/medline/citation/12425538/Nonalcoholic_steatohepatitis:_what_we_know_in_the_new_millennium_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0002-9270&date=2002&volume=97&issue=11&spage=2714 DB - PRIME DP - Unbound Medicine ER -